Company also announces FDA approval of TAXUS(R) Express2(TM) Stent System

for treatment of in-stent restenosis

NATICK, Mass., Sept. 25 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX) today announced that it has received approval from
the U.S. Food and Drug Administration (FDA) to market its TAXUS(R)
Express2(TM) Atom(TM) Paclitaxel-Eluting Coronary Stent System. The TAXUS
Express Atom Stent is a highly deliverable drug-eluting stent (DES)
specifically designed for treating small coronary vessels. It is the only
DES approved by the FDA for use in vessels as small as 2.25 mm in diameter.
No other DES for sale in the U.S. market is approved for use in vessels
smaller than 2.50 mm in diameter. The Company plans to launch the product
immediately.

The Company today also announced FDA approval of its TAXUS(R)
Express2(TM) Paclitaxel-Eluting Coronary Stent System for the treatment of
in-stent restenosis in bare-metal stents. This is the first such approval
granted by the FDA, making the TAXUS Express2 Stent System the only
drug-eluting stent approved in the United States for the treatment of
in-stent restenosis in bare-metal stents.

"The TAXUS Express Atom Stent will provide better options for U.S.
patients with coronary artery disease in small vessels," said Gregg Stone,
M.D., Chairman of the Cardiovascular Research Foundation and Professor of
Medicine at Columbia University Medical Center, and Principal Investigator
of the TAXUS IV and V clinical trials. "This is a welcome addition to the
range of available drug-eluting stents, since patients with small vessels
who are currently treated with bare-metal stents experience high rates of
restenosis. In the TAXUS V clinical trial, the TAXUS Express Atom Stent
significantly reduced the chance of restenosis and the need for repeat
procedures compared to bare-metal stents, in patients with small vessel
disease."

"Our TAXUS Express Atom Stent addresses an unmet need and will help
interventional cardiologists better treat small vessel disease," said Jim
Tobin, President and Chief Executive Officer of Boston Scientific. "With
the recent FDA approval of our PROMUS(TM) Stent and now the TAXUS Express
Atom Stent for small vessels, Boston Scientific offers the most
comprehensive DES portfolio in the industry, offering physicians and their
patients the broadest size matrix and the industry's only two-drug
platform."

"In addition to being a welcome product approval, we believe this is
also an important indication we have made significant progress toward
resolving the issues related to the Corporate Warning Letter," added Tobin.

TAXUS stents have been evaluated by the industry's most extensive
randomized, controlled clinical trial program, with follow-up to five years
in some cases. These trial results have been supplemented by data on more
than 35,000 patients enrolled in post-approval registries. To date,
approximately 4.6 million TAXUS stents have been implanted globally, making
them the world's most frequently used drug-eluting stents.

Boston Scientific is a worldwide developer, manufacturer and marketer
of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like "anticipate,"
"expect," "project," "believe," "plan," "estimate," "intend" and similar
words. These forward-looking statements are based on our beliefs,
assumptions and estimates using information available to us at the time and
are not intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding clinical trials, product performance, competitive offerings,
procedural volume, overall market size and our market position. If our
underlying assumptions turn out to be incorrect, or if certain risks or
uncertainties materialize, actual results could vary materially from the
expectations and projections expressed or implied by our forward-looking
statements. These factors, in some cases, have affected and in the future
(together with other factors) could affect our ability to implement our
business strategy and may cause actual results to differ materially from
those contemplated by the statements expressed in this press release. As a
result, readers are cautioned not to place undue reliance on any of our
forward-looking statements.

Factors that may cause such differences include, among other things:
future economic, competitive, reimbursement and regulatory conditions; new
product introductions; demographic trends; intellectual property;
litigation; financial market conditions; and, future business decisions
made by us and our competitors. All of these factors are difficult or
impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A -
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A
- Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
thereafter. We disclaim any intention or obligation to publicly update or
revise any forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

(Date:12/9/2016)... York , December 9, 2016 ... that the top five players in the Global Label-Free ... in the overall market in 2015. Players such as ... Elmer have remained dominant in the global market due ... to ensure product innovation. Product upgrades and timely product ...

(Date:11/21/2016)... , Nov. 21, 2016 Neurotechnology ... object recognition technologies, today announced that the MegaMatcher ... cards was submitted for the NIST Minutiae ... passed all the mandatory steps of the evaluation ... is a continuing test of fingerprint templates used ...